CryoLife
This article was originally published in The Gray Sheet
Executive Summary
Board authorizes repurchase of up to 1 mil. shares of common stock. Separately, the Atlanta-based maker of human tissue implantable devices reported a 10% increase in third quarter revenues to $16 mil. Net income, excluding effects of the sale of the firm's Ideas for Medicine business, was up 31% to $1.9 mil. Including the sale, net income was up 118.7% to $3.2 mil
|
Board authorizes repurchase of up to 1 mil. shares of common stock. Separately, the Atlanta-based maker of human tissue implantable devices reported a 10% increase in third quarter revenues to $16 mil. Net income, excluding effects of the sale of the firm's Ideas for Medicine business, was up 31% to $1.9 mil. Including the sale, net income was up 118.7% to $3.2 mil. |